|
TTPAL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.41699995970646E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.93780000116107E-08 |
| Normal-vs-Stage2 |
2.673500E-02 |
| Normal-vs-Stage3 |
1.36809996664766E-09 |
| Normal-vs-Stage4 |
1.05739999978205E-07 |
| Stage1-vs-Stage2 |
4.296400E-02 |
| Stage1-vs-Stage3 |
6.970000E-02 |
| Stage1-vs-Stage4 |
6.174500E-02 |
| Stage2-vs-Stage3 |
2.702000E-03 |
| Stage2-vs-Stage4 |
5.497400E-03 |
| Stage3-vs-Stage4 |
6.234400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.62610000412167E-09 |
| Normal-vs-AfricanAmerican |
3.216400E-03 |
| Normal-vs-Asian |
2.0969999999787E-06 |
| Caucasian-vs-AfricanAmerican |
5.200200E-01 |
| Caucasian-vs-Asian |
9.361600E-01 |
| AfricanAmerican-vs-Asian |
5.064200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.01169999734108E-08 |
| Normal-vs-Female |
1.99020000479777E-08 |
| Male-vs-Female |
2.636600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.02959999707053E-08 |
| Normal-vs-Age(41-60Yrs) |
5.01539999975265E-07 |
| Normal-vs-Age(61-80Yrs) |
1.73069999997999E-07 |
| Normal-vs-Age(81-100Yrs) |
4.675500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.701000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.035800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.692000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.128200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.014200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.642200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.773910E-02 |
| Classical-VS-Follicular |
2.645000E-01 |
| Classical-VS-Other |
2.519400E-01 |
| Classical-VS-Normal |
4.12249999692804E-08 |
| Tall-VS-Follicular |
2.001300E-03 |
| Tall-VS-Other |
9.354800E-01 |
| Tall-VS-Normal |
8.13839995394972E-09 |
| Follicular-VS-Other |
1.936380E-01 |
| Follicular-VS-Normal |
1.037330E-03 |
| Other-VS-Normal |
2.995100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.18059999998366E-06 |
| Normal-vs-N1 |
2.45269999865627E-08 |
| N0-vs-N1 |
1.981780E-02 |
|
|
